Abstract
Pure red cell aplasia (PRCA) is a rare bone marrow (BM) disorder characterized by ineffective erythropoiesis, reduced reticulocyte count, normocytic anemia, and the absence of erythroid precursors. Here, we present a rare instance of PRCA occurring after ABO-matched allo-HSCT in a refractory/relapsed acute myeloid leukemia (R/R AML) patient. In this case, the patient received a combination treatment of Gilteritinib, Venetoclax, and Azacitidine. Remarkably, this treatment not only reduced myeloblasts but also facilitated the restoration of erythroid hematopoiesis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
The original contributions presented in the study are included in the article. Further inquiries can be directed to the corresponding author.
References
Sawada K, Fujishima N, Hirokawa M (2008) Acquired pure red cell aplasia: updated review of treatment. Br J Haematol 142(4):505–514
Longval T et al (2021) Treatment for pure red cell aplasia after major ABO-incompatible allogeneic stem cell transplantation: a multicentre study. Br J Haematol 193(4):814–826
Jung SH et al (2012) Successful treatment of pure red cell aplasia with Rituximab in patients after ABO-Compatible allogeneic hematopoietic stem cell transplantation. Case Rep Oncol 5(1):110–113
Salas MQ, Alahmari A, Lipton JH (2020) Successful treatment of refractory red cell aplasia after allogeneic hematopoietic cell transplantation with daratumumab. Eur J Haematol 104(2):145–147
Marco-Ayala J et al (2021) Pure red cell aplasia after major or bidirectional ABO incompatible hematopoietic stem cell transplantation: to treat or not to treat, that is the question. Bone Marrow Transpl 56(4):769–778
Chapuy CI et al (2018) Daratumumab for delayed red-cell engraftment after allogeneic transplantation. N Engl J Med 379(19):1846–1850
Roychowdhury DF, Linker CA (1995) Pure red cell aplasia complicating an ABO-compatible allogeneic bone marrow transplantation, treated successfully with antithymocyte globulin. Bone Marrow Transpl 16(3):471–472
Saunthararajah Y et al (2003) Effects of 5-aza-2’-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. Blood 102(12):3865–3870
Funding
This work was supported by the National Natural Science Foundation of China (Grant No. 81470329).
Author information
Authors and Affiliations
Contributions
WJW wrote the main manuscript text and analyzed the data. ZH collected and analyzed the data. MKR supervised the study. All authors reviewed the manuscript.
Corresponding author
Ethics declarations
Ethical approval
Written informed consent was obtained from the patient for the publication of any potentially identifable data included in this article.
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Wang, J., Zhu, H. & Miao, K. Gilteritinib combined with venetoclax and azacitidine for relapsed acute myeloid leukemia cocurrent with pure red cell aplasia after allogeneic hematopoietic stem cell transplantation: a case report. Ann Hematol 103, 1775–1777 (2024). https://doi.org/10.1007/s00277-024-05714-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-024-05714-y